Journal Article
. 2014 Apr; 3(1):e27614.
doi: 10.4161/onci.27614.

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Linda C Sandin 1 Fredrik Eriksson 1 Peter Ellmark 2 Angelica Si Loskog 1 Thomas H Tötterman 1 Sara M Mangsbo 1 
  • PMID: 24701377
  •     34 References
  •     35 citations


Antibody-mediated blockade of CTLA4 has been shown to be effective in treating a select group of patients with late-stage melanoma. The precise mechanism underlying the clinical activity of CTLA4 immunotherapy is poorly understood, although recent experimental findings indicate that antibody-mediated depletion of regulatory T cells (Tregs) in the tumor microenvironment plays a key role in efficacious antitumor responses. In the current study, we used an experimental model of pancreatic adenocarcinoma to compare the antitumor efficacy of peritumoral low-dose anti-CTLA4 monoclonal antibody (mAb) administration to that of a commonly utilized systemic high-dose anti-CTLA4 regimen. We selected pancreatic adenocarcinoma as it presents a particular challenge to clinicians due to its aggressive behavior, metastatic spread and limited treatment options. Furthermore, Fc gamma receptor (FcγR)-dense myeloid cells commonly infiltrate pancreatic tumors, such that these tumor types exhibit increased susceptibility to CTLA4 antibody-targeted Treg depletion via antibody-dependent cell-mediated cytotoxicity (ADCC). Locally administered anti-CTLA4 mAb effectively reduced tumor growth at a low dose and no additional anti-tumor effects were apparent when increasing the dose or number of injections. No significant difference in overall survival was seen when comparing locally administered low-dose with standard systemic high-dose CTLA4 blockade therapy, and both delivery routes led to increased tumor-infiltrating effector T cells and reduced Treg cells. As opposed to low-dose peritumoral treatment, high-dose systemic therapy stimulated the accumulation of Tregs in secondary lymphoid organs, an effect that could potentially counteract the antitumor immunotherapeutic benefit of CTLA4 blockade. Our study confirms previous findings that local administration of low-dose anti-CTLA4 antibody generates sustained antitumor effects and provides rationale to devise ultrasound-guided intratumoral anti-CTLA4 antibody injection regimens to treat patients with pancreatic adenocarcinoma and other types of solid tumors. In support, clinical relevancy could include reduced immune-related adverse events by limiting systemic antibody spread to immune cell-dense organs.

Keywords: anti-CTLA4; checkpoint blockade; immunotherapy; local therapy; pancreatic cancer.

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
Dung T Le, Eric Lutz, +8 authors, Daniel A Laheru.
J Immunother, 2013 Aug 09; 36(7). PMID: 23924790    Free PMC article.
Highly Cited.
Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease.
Nicola Eastaff-Leung, Nicholas Mabarrack, +2 authors, Simon Barry.
J Clin Immunol, 2009 Nov 26; 30(1). PMID: 19936899
Highly Cited.
Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
Asim Saha, S K Chatterjee.
Scand J Immunol, 2010 Apr 14; 71(2). PMID: 20384858
Ipilimumab: first global approval.
Fiona Cameron, Glenn Whiteside, Caroline Perry.
Drugs, 2011 Jun 15; 71(8). PMID: 21668044
Current concepts and novel targets in advanced pancreatic cancer.
Patrick Michl, Thomas M Gress.
Gut, 2012 Nov 01; 62(2). PMID: 23112132
Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells.
Christian Mottet, Holm H Uhlig, Fiona Powrie.
J Immunol, 2003 Apr 12; 170(8). PMID: 12682220
Highly Cited.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
H A Burris, M J Moore, +11 authors, D D Von Hoff.
J Clin Oncol, 1997 Jun 01; 15(6). PMID: 9196156
Highly Cited.
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Karl S Peggs, Sergio A Quezada, +2 authors, James P Allison.
J Exp Med, 2009 Jul 08; 206(8). PMID: 19581407    Free PMC article.
Highly Cited.
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.
Marieke F Fransen, Tetje C van der Sluis, +2 authors, Cornelis J M Melief.
Clin Cancer Res, 2013 Jun 22; 19(19). PMID: 23788581
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion.
Anthony Evans, Eithne Costello.
Front Physiol, 2012 Sep 13; 3. PMID: 22969725    Free PMC article.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Sebastian Tuve, Bing-Mae Chen, +10 authors, André Lieber.
Cancer Res, 2007 Jun 19; 67(12). PMID: 17575163
Cancer statistics, 2012.
Rebecca Siegel, Deepa Naishadham, Ahmedin Jemal.
CA Cancer J Clin, 2012 Jan 13; 62(1). PMID: 22237781
Highly Cited.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Sara M Mangsbo, Linda C Sandin, +3 authors, Thomas H Tötterman.
J Immunother, 2010 May 07; 33(3). PMID: 20445343
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
R P Sutmuller, L M van Duivenvoorde, +6 authors, C J Melief.
J Exp Med, 2001 Sep 19; 194(6). PMID: 11560997    Free PMC article.
Highly Cited.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo.
Oliver M Grauer, Stefan Nierkens, +5 authors, Gosse J Adema.
Int J Cancer, 2007 Feb 23; 121(1). PMID: 17315190
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
Brian Kavanagh, Shaun O'Brien, +6 authors, Lawrence Fong.
Blood, 2008 Jun 05; 112(4). PMID: 18523152    Free PMC article.
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Geoffrey Y Ku, Jianda Yuan, +7 authors, Jedd D Wolchok.
Cancer, 2010 Feb 10; 116(7). PMID: 20143434    Free PMC article.
Highly Cited.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
Peter Attia, Giao Q Phan, +14 authors, Steven A Rosenberg.
J Clin Oncol, 2005 Aug 10; 23(25). PMID: 16087944    Free PMC article.
Highly Cited.
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
C A Chambers, M S Kuhns, J G Egen, J P Allison.
Annu Rev Immunol, 2001 Mar 13; 19. PMID: 11244047
Highly Cited. Review.
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Michael A Curran, Myoungjoo Kim, +2 authors, James P Allison.
PLoS One, 2011 May 12; 6(4). PMID: 21559358    Free PMC article.
Highly Cited.
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.
S Read, V Malmström, F Powrie.
J Exp Med, 2000 Jul 19; 192(2). PMID: 10899916    Free PMC article.
Highly Cited.
Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.
Ivan Shevchenko, Svetlana Karakhanova, +5 authors, Alexandr V Bazhin.
Int J Cancer, 2012 Dec 13; 133(1). PMID: 23233419
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
Jedd D Wolchok, Bart Neyns, +14 authors, Celeste Lebbé.
Lancet Oncol, 2009 Dec 17; 11(2). PMID: 20004617
Highly Cited.
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.
Aurélien Marabelle, Holbrook Kohrt, Ronald Levy.
Clin Cancer Res, 2013 Aug 24; 19(19). PMID: 23965900    Free PMC article.
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.
Richard E Royal, Catherine Levy, +8 authors, Steven A Rosenberg.
J Immunother, 2010 Sep 16; 33(8). PMID: 20842054    Free PMC article.
Highly Cited.
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Sergio A Quezada, Karl S Peggs, Michael A Curran, James P Allison.
J Clin Invest, 2006 Jun 17; 116(7). PMID: 16778987    Free PMC article.
Highly Cited.
Monoclonal antibodies and other targeted therapies for pancreatic cancer.
Pelin Cinar, Margaret A Tempero.
Cancer J, 2012 Nov 29; 18(6). PMID: 23187854
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Linda C Sandin, Anna Orlova, +4 authors, Sara M Mangsbo.
Cancer Immunol Res, 2014 Apr 30; 2(1). PMID: 24778163
Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity.
Andrew D Simmons, Marina Moskalenko, +5 authors, Karin Jooss.
Cancer Immunol Immunother, 2008 Feb 01; 57(8). PMID: 18236040
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Rafael Winograd, Katelyn T Byrne, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2015 Feb 14; 3(4). PMID: 25678581    Free PMC article.
Highly Cited.
Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.
Christel Devaud, Jennifer A Westwood, +6 authors, Michael H Kershaw.
Oncoimmunology, 2015 May 06; 3(11). PMID: 25941590    Free PMC article.
Novel immune checkpoint blocker approved for the treatment of advanced melanoma.
Lorenzo Galluzzi, Guido Kroemer, Alexander Eggermont.
Oncoimmunology, 2015 May 06; 3(11). PMID: 25941597    Free PMC article.
Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.
Peter Duewell, Ebba Beller, +7 authors, Max Schnurr.
Oncoimmunology, 2015 Oct 28; 4(10). PMID: 26504669    Free PMC article.
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
Nadia M Luheshi, Jane Coates-Ulrichsen, +8 authors, Robert W Wilkinson.
Oncotarget, 2016 Feb 27; 7(14). PMID: 26918344    Free PMC article.
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.
Kristina Iribarren, Norma Bloy, +9 authors, Lorenzo Galluzzi.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141345    Free PMC article.
Highly Cited. Review.
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.
Peter Ellmark, Sara M Mangsbo, +2 authors, Thomas H Tötterman.
Cancer Immunol Immunother, 2016 Oct 08; 66(1). PMID: 27714433    Free PMC article.
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.
Mee Y Bartee, Katherine M Dunlap, Eric Bartee.
Cancer Res, 2017 Mar 21; 77(11). PMID: 28314785    Free PMC article.
Highly Cited.
The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs.
Aditya Arra, Holger Lingel, +6 authors, Monika C Brunner-Weinzierl.
Oncoimmunology, 2017 Mar 28; 6(2). PMID: 28344884    Free PMC article.
CAR T-cell therapy for pancreatic cancer.
Carl J DeSelm, Zachary E Tano, Anna M Varghese, Prasad S Adusumilli.
J Surg Oncol, 2017 Mar 28; 116(1). PMID: 28346697    Free PMC article.
Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy.
David M Francis, Susan N Thomas.
Adv Drug Deliv Rev, 2017 Apr 30; 114. PMID: 28455187    Free PMC article.
Synthetic immune niches for cancer immunotherapy.
Jorieke Weiden, Jurjen Tel, Carl G Figdor.
Nat Rev Immunol, 2017 Aug 31; 18(3). PMID: 28853444
Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.
Neus Martinez-Bosch, Judith Vinaixa, Pilar Navarro.
Cancers (Basel), 2018 Jan 06; 10(1). PMID: 29301364    Free PMC article.
Highly Cited. Review.
Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.
Vishal Jindal, Ena Arora, Muhammad Masab, Sorab Gupta.
Med Oncol, 2018 May 08; 35(6). PMID: 29728788
New opportunities for nanoparticles in cancer immunotherapy.
Wooram Park, Young-Jae Heo, Dong Keun Han.
Biomater Res, 2018 Oct 03; 22. PMID: 30275967    Free PMC article.
Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy.
Sunkuk Kwon, Fred Christian Velasquez, +7 authors, Eva M Sevick-Muraca.
Theranostics, 2019 Nov 23; 9(26). PMID: 31754400    Free PMC article.
Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
Luisa Barrueto, Francheska Caminero, +3 authors, Rahul R Deshmukh.
Transl Oncol, 2020 Mar 03; 13(3). PMID: 32114384    Free PMC article.
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Chien-Chun Steven Pai, Donald M Simons, +22 authors, Lawrence Fong.
J Clin Invest, 2018 Dec 12; 129(1). PMID: 30530991    Free PMC article.
A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
Hayley S Ma, Bibhav Poudel, +9 authors, Elizabeth M Jaffee.
Cancer Immunol Res, 2019 Jan 16; 7(3). PMID: 30642833    Free PMC article.
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Anne Månsson Kvarnhammar, Niina Veitonmäki, +16 authors, Peter Ellmark.
J Immunother Cancer, 2019 Apr 13; 7(1). PMID: 30975201    Free PMC article.
Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies.
Lambros Tselikas, Thierry de Baere, +9 authors, Aurélien Marabelle.
J Immunother Cancer, 2020 Jun 24; 8(1). PMID: 32571995    Free PMC article.
RNA-electroporated T cells for cancer immunotherapy.
Fernanda Pohl-Guimarães, Lan B Hoang-Minh, Duane A Mitchell.
Oncoimmunology, 2020 Oct 27; 9(1). PMID: 33101771    Free PMC article.
Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma.
J M Moskovitz, R L Ferris.
J Dent Res, 2018 Mar 01; 97(6). PMID: 29489423    Free PMC article.
TAMing pancreatic cancer: combat with a double edged sword.
Manendra Babu Lankadasari, Pramiti Mukhopadhyay, Sabira Mohammed, Kuzhuvelil B Harikumar.
Mol Cancer, 2019 Mar 31; 18(1). PMID: 30925924    Free PMC article.
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives.
Alessandra Lopes, Gaëlle Vandermeulen, Véronique Préat.
J Exp Clin Cancer Res, 2019 Apr 07; 38(1). PMID: 30953535    Free PMC article.
Advances in engineering local drug delivery systems for cancer immunotherapy.
Peter Abdou, Zejun Wang, +4 authors, Zhen Gu.
Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2020 Apr 08; 12(5). PMID: 32255276    Free PMC article.
Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies.
Thao N D Pham, Mario A Shields, +6 authors, Hidayatullah G Munshi.
Cancers (Basel), 2021 Jan 29; 13(3). PMID: 33503832    Free PMC article.
UXT antisense RNA 1 sever as a novel prognostic long non-coding RNA in early stage pancreatic ductal adenocarcinoma patients after receiving pancreaticoduodenectomy.
Xiwen Liao, Rui Huang, +9 authors, Tao Peng.
J Cancer, 2021 Mar 24; 12(7). PMID: 33754011    Free PMC article.
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy.
Navid Sobhani, Dana Rae Tardiel-Cyril, +3 authors, Yong Li.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33809974    Free PMC article.
Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy.
Florentine E F Timmer, Bart Geboers, +7 authors, Martijn R Meijerink.
Curr Oncol Rep, 2021 Apr 18; 23(6). PMID: 33864144    Free PMC article.
Intratumoural administration and tumour tissue targeting of cancer immunotherapies.
Ignacio Melero, Eduardo Castanon, +2 authors, Aurelien Marabelle.
Nat Rev Clin Oncol, 2021 May 20; 18(9). PMID: 34006998    Free PMC article.
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
Alexa C Glencer, Jasmine M Wong, +7 authors, Michael J Campbell.
NPJ Breast Cancer, 2021 May 27; 7(1). PMID: 34035311    Free PMC article.
Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights.
Marieke F Fransen, Thorbald van Hall, Ferry Ossendorp.
Int J Mol Sci, 2021 Sep 11; 22(17). PMID: 34502307    Free PMC article.
Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.
Roland E Kontermann, Guy Ungerechts, Dirk M Nettelbeck.
MAbs, 2021 Nov 09; 13(1). PMID: 34747345    Free PMC article.
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.
Alexandr V Bazhin, Katharina von Ahn, +6 authors, Svetlana Karakhanova.
Oncoimmunology, 2022 Mar 08; 11(1). PMID: 35251770    Free PMC article.